Uwe M. Martens

12.3k total citations
103 papers, 4.2k citations indexed

About

Uwe M. Martens is a scholar working on Oncology, Molecular Biology and Physiology. According to data from OpenAlex, Uwe M. Martens has authored 103 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 26 papers in Molecular Biology and 26 papers in Physiology. Recurrent topics in Uwe M. Martens's work include Telomeres, Telomerase, and Senescence (26 papers), Colorectal Cancer Treatments and Studies (21 papers) and Gastric Cancer Management and Outcomes (12 papers). Uwe M. Martens is often cited by papers focused on Telomeres, Telomerase, and Senescence (26 papers), Colorectal Cancer Treatments and Studies (21 papers) and Gastric Cancer Management and Outcomes (12 papers). Uwe M. Martens collaborates with scholars based in Germany, Spain and United States. Uwe M. Martens's co-authors include Peter M. Lansdorp, Steven S.S. Poon, Rabab Ward, Stefan Zimmermann, J. M. J. M. Zijlmans, Elizabeth A. Chavez, Cornelius F. Waller, Anton K. Raap, Hans J. Tanke and Jane Yui and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Uwe M. Martens

99 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Uwe M. Martens Germany	32	1.6k	1.6k	1.4k	567	499	103	4.2k
Ante S. Lundberg United States	17	3.0k 1.8×	1.1k 0.7×	1.7k 1.3×	444 0.8×	329 0.7×	39	4.7k
P. Sivaramakrishna Rachakonda Germany	25	1.9k 1.2×	1.0k 0.6×	931 0.7×	291 0.5×	304 0.6×	45	3.4k
Hesed Padilla‐Nash United States	28	2.1k 1.3×	479 0.3×	737 0.5×	158 0.3×	302 0.6×	56	3.9k
John D. Crispino United States	52	5.0k 3.1×	664 0.4×	698 0.5×	985 1.7×	481 1.0×	168	8.1k
Najet Debili France	54	2.6k 1.6×	473 0.3×	739 0.5×	1.2k 2.2×	1.2k 2.5×	147	8.3k
Deborah J. Marsh Australia	43	4.2k 2.6×	312 0.2×	1.8k 1.3×	542 1.0×	456 0.9×	130	7.4k
Edward F. Fritsch United States	18	2.1k 1.3×	374 0.2×	948 0.7×	1.1k 1.9×	194 0.4×	25	4.1k
Jean Benhattar Switzerland	43	2.3k 1.4×	680 0.4×	2.2k 1.6×	256 0.5×	1.4k 2.8×	114	5.5k
Elizabeth Hyjek United States	29	1.1k 0.6×	282 0.2×	1.8k 1.3×	799 1.4×	356 0.7×	68	3.6k
Carlos A. Torres‐Cabala United States	34	2.4k 1.5×	480 0.3×	2.0k 1.5×	597 1.1×	1.5k 3.0×	214	5.0k

Countries citing papers authored by Uwe M. Martens

Since Specialization

Citations

This map shows the geographic impact of Uwe M. Martens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe M. Martens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe M. Martens more than expected).

Fields of papers citing papers by Uwe M. Martens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uwe M. Martens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe M. Martens. The network helps show where Uwe M. Martens may publish in the future.

Co-authorship network of co-authors of Uwe M. Martens

This figure shows the co-authorship network connecting the top 25 collaborators of Uwe M. Martens. A scholar is included among the top collaborators of Uwe M. Martens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uwe M. Martens. Uwe M. Martens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2023). O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG. Annals of Oncology. 34. S182–S182. 3 indexed citations

Arnold, Dirk, Eray Goekkurt, Alexander Stein, et al.. (2023). 1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study. Annals of Oncology. 34. S899–S899. 5 indexed citations

Martens, Uwe M., et al.. (2023). Assessing Quality of Life Using FHIR – How to Combine Patient Reported Outcome with Patient Generated Data for Better Compliance. Studies in health technology and informatics. 302. 135–136. 1 indexed citations

Ferris, Robert L., William C. Spanos, Rom S. Leidner, et al.. (2021). Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. Journal for ImmunoTherapy of Cancer. 9(6). e002568–e002568. 126 indexed citations

Vogel, Arndt, Anna Saborowski, Thomas J. Ettrich, et al.. (2021). LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC). Annals of Oncology. 32. S1312–S1312. 8 indexed citations

Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2019). EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 19(1). 494–494. 87 indexed citations

Pobiruchin, Monika, Sylvia Bochum, Uwe M. Martens, & W Schramm. (2016). Clinical Cancer Registries - Are They Up for Health Services Research?. PubMed. 228. 242–6. 1 indexed citations

Pobiruchin, Monika, Sylvia Bochum, Uwe M. Martens, Meinhard Kieser, & W Schramm. (2016). Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset. Data in Brief. 7. 654–657. 2 indexed citations

Pobiruchin, Monika, et al.. (2015). Prediction of 5-Year Survival with Data Mining Algorithms. Studies in health technology and informatics. 213. 75–8. 8 indexed citations

10.

Elez, Élena, Ilona Kocáková, Thomas Höhler, et al.. (2014). Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Annals of Oncology. 26(1). 132–140. 89 indexed citations

11.

Biniossek, Martin L., André Lechel, K. Lenhard Rudolph, Uwe M. Martens, & Stefan Zimmermann. (2013). Quantitative proteomic profiling of tumor cell response to telomere dysfunction using isotope-coded protein labeling (ICPL) reveals interaction network of candidate senescence markers. Journal of Proteomics. 91. 515–535. 16 indexed citations

12.

Halama, Niels, Sara Michel, Matthias Kloor, et al.. (2011). Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy. Cancer Research. 71(17). 5670–5677. 321 indexed citations

13.

Martens, Uwe M., et al.. (2007). Telomerase Inhibition and Telomere Targeting in Hematopoietic Cancer Cell Lines with Small Non-Nucleosidic Synthetic Compounds (BIBR1532). Methods in molecular biology. 405. 47–60. 15 indexed citations

14.

Lansdorp, Peter M., Steven S.S. Poon, Elizabeth A. Chavez, et al.. (2007). Telomeres in the Haemopoietic System. Novartis Foundation symposium. 211. 209–226. 4 indexed citations

15.

Müller, Antonia, Uwe M. Martens, Silke Hofmann, et al.. (2005). Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Annals of Hematology. 85(1). 1–16. 34 indexed citations

16.

Zimmermann, Stefan & Uwe M. Martens. (2005). Telomere Dynamics in Hematopoietic Stem Cells. Current Molecular Medicine. 5(2). 179–185. 17 indexed citations

17.

Ketteler, Robin, Sven Gläser, Olivier Sandra, Uwe M. Martens, & Ursula Klingmüller. (2002). Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors. Gene Therapy. 9(8). 477–487. 80 indexed citations

18.

Poon, Steven S.S., Uwe M. Martens, Rabab Ward, & Peter M. Lansdorp. (1999). Telomere length measurements using digital fluorescence microscopy. Cytometry. 36(4). 267–278. 203 indexed citations

19.

Zijlmans, J. M. J. M., Uwe M. Martens, Steven S.S. Poon, et al.. (1997). Telomeres in the mouse have large inter-chromosomal variations in the number of T ₂ AG ₃ repeats. Proceedings of the National Academy of Sciences. 94(14). 7423–7428. 423 indexed citations

20.

Brennscheidt, U., Dirk Eick, Regina Kunzmann, et al.. (1994). Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemia.. PubMed. 8(5). 897–902. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact